Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and Myc activity downstream of platelet-derived growth factor receptor

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7400-7410

  Dafni, Hagit ^a   Larson, Peder E Z ^a   Hu, Simon ^a   Yoshihara, Hikari A I ^a   Ward, Christopher S ^a   Venkatesh, Humsa S ^a   Wang, Chunsheng ^a   Zhang, Xiaoliang ^a   Vigneron, Daniel B ^a   Ronen, Sabrina M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; LACTATE DEHYDROGENASE; MYC PROTEIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR; CARBON; LACTIC ACID; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HYPERPOLARIZATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; BIOSYNTHESIS; CAPILLARY PERMEABILITY; DRUG ANTAGONISM; HUMAN; MALE; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CARBON ISOTOPES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; L-LACTATE DEHYDROGENASE; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PIPERAZINES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957343186     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0883     Document Type: Article

References (53)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
3. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
4. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. Oncologist 2008;13:25-38.
5. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008;49 Suppl 2:24-42S.
6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
7. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
8. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-43.
9. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
10. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13 Suppl 2:8-13.
11. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004;10:6661-8.
12. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to- noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158-63.
13. Golman K, in 't Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci U S A 2006;103:11270-5.
14. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.
15. Ward CS, Venkatesh HS, Chaumeil MM, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 2010;70:1296-305.
16. Dafni H, Kim SJ, Bankson JA, Sankaranarayanapillai M, Ronen SM. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008;60:822-33.
17. 13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med 2010;63:582-91.
18. Dafni H, Gilead A, Nevo N, Eilam R, Harmelin A, Neeman M. Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin. Magn Reson Med 2003;50:904-14.
19. Dafni H, Israely T, Bhujwalla ZM, Benjamin LE, Neeman M. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. Cancer Res 2002;62:6731-9.
20. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
21. 13C NMR studies. Proc Natl Acad Sci U S A 1989;86:5585-9.
22. 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta 1991;1095:5-16.
23. 13C-labeled glutamine. Magn Reson Med 2008;60:253-7.
24. Chen YH, Lin SJ, Ku HH, et al. Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-α-treated human aortic endothelial cells. J Cell Biochem 2001;82:512-21.
25. Vassault A. Lactate dehydrogenase. UV-method with pyruvate and NADH. In: Bergmeyer HU, editor. Methods of enzymatic analysis. 3. Weinheim: Verlag Chemie; 1983, p. 118-26.
26. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem 1973;53:452-8.
27. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70.
28. Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006;98:783-93.
29. Mathew P, Pisters LL, Wood CG, et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009;181:81-7; discussion 7.
30. Schroeder MA, Atherton HJ, Cochlin LE, Clarke K, Radda GK, Tyler DJ. The effect of hyperpolarized tracer concentration on myocardial uptake and metabolism. Magn Reson Med 2009;61:1007-14.
31. Kohler SJ, Yen Y, Wolber J, et al. In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med 2007;58:65-9.
32. Hu S, Chen AP, Zierhut ML, et al. In vivo carbon-13 dynamic MRS and MRSI of normal and fasted rat liver with hyperpolarized (13)C-pyruvate. Mol Imaging Biol 2009;11:399-407.
33. 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006;66:10855-60.
34. 13C1-pyruvate transport and metabolism in living human breast cancer cells. Proc Natl Acad Sci U S A 2009;106:18131-6.
35. Witney TH, Kettunen MI, Day SE, et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009;11:574-82, 1 p following 82.
36. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
37. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13.
38. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795:162-72.
39. Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004;64:6563-70.
40. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16:2530-43.
41. Shchors K, Shchors E, Rostker F, LawlorER, Brown-Swigart L, Evan GI. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β. Genes Dev 2006;20:2527-38.
42. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105.
43. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
44. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-81.
45. Hong H, Zhang Y, Sun J, Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 2009;39:11-27.
46. 13C-labelled bicarbonate. Nature 2008;453:940-3.
47. Gallagher FA, Kettunen MI, Hu DE, et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A 2009;106:19801-6.
48. 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010;12:133-44.
49. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008;68:8607-15.
50. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
51. Iavarone C, Catania A, Marinissen MJ, et al. The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. J Biol Chem 2003;278:50024-30.
52. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27:7381-93.
53. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR- 23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.